CD274 and non-small cell lung carcinoma: For instance, a comparative study retrospectively screened patients with pathologically confirmed advanced or recurrent NSCLC demontrated that the HPD rate was significantly lower in the combination therapy (cytotoxic chemotherapy plus PD-1/PD-L1 inhibitor) group than in the PD-1/PD-L1 inhibitor monotherapy group (61).